GRANULEMATOZ POLIANGIIT NEGIZIDA KECHUVCHI RINOSINUSITLI BEMORLARDA ANEMIYA VA YALLIG‘LANISH MARKERLARINING DIFFERENSIAL TASHXISDAGI AHAMIYATI
DOI:
https://doi.org/10.57231/j.ejohns.2025.4.4.008Ключевые слова:
poliangiitli granulematoz, rinosinusit, anemiya, yallig‘lanish markerlari, umumiy qon tahlili, tizimli vaskulit, diff erensial diagnostikaАннотация
Maqsad – poliangiitli granulematoz (PG) fonida rinosinusit bilan og‘rigan bemorlarda anemiya va
yallig‘lanish markerlarining (gemoglobin, gematokrit, ECHT, leykotsitlar, trombotsitlar) diff erensial diagnostik ahamiyatini
baholash. Tadqiqotga PG tashxisi qo‘yilgan 3 ta klinik guruh va surunkali rinosinusitli nazorat bemorlari kiritildi. Barcha
bemorlarga standart LOR-ko‘rik bilan bir qatorda umumiy qon tahlili bajarilib, ko‘rsatkichlar kasallik bosqichi va
tizimli shikastlanish darajasi bilan taqqoslandi. PG guruhlarida normotsitar anemiya, ECHT ning keskin oshishi, reaktiv
leykotsitoz va trombotsitlar sonidagi o‘zgarishlar oddiy surunkali rinosinusitga nisbatan ancha yaqqol kuzatildi. Qon
ko‘rsatkichlarining kombinatsiyalangan o‘zgarishi ANCA ijobiyligi va buyrak ishtiroki bilan muvo# qlikda bo‘lib, tizimli
vaskulit ehtimolini erta taxmin qilish imkonini berdi. Xulosa qilib, anemiya va yallig‘lanish markerlarini kompleks tahlili
PG bilan bog‘liq rinosinusitlarni odatiy LOR-patologiyalardan farqlashda oddiy, ammo ishonchli laborator mezon sifatida
taklif etiladi.
Библиографические ссылки
Hunter RW, Welsh N, Farrah TE, Gallacher PJ. ANCAassociated vasculitis. BMJ. 2020;369:m1070.
Austin K, Janagan S, Wells M, et al. ANCA associated vasculitis subtypes: recent insights and future perspectives.J In$ amm Res. 2022;15:2567–2582.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCAassociated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30–47.
KDIGO ANCA Vasculitis Work Group. KDIGO 2024 clinical practice guideline for the management of ANCAassociated vasculitis. Kidney Int. 2024;105(3S):S71–S116.
Delvino P, La Rocca G, et al. Systemic vasculitis: one year in review 2025. Clin Exp Rheumatol. 2025;43(Suppl.).
Drouzas K, Gougourelas I, Tsiakalos A, et al. Current understanding of the pathogenesis of ANCA-associated vasculitis. Life (Basel). 2025;15(5):756.
Almeida S, Neves PM, Domingues VDS. Pathogenesis and biomarkers in ANCA-associated vasculitis. Vessel Plus. 2021;5:27.
Morris AD, Rowbottom AW, Martin FL, Woywodt A, Dhaygude AP. Biomarkers in ANCA-associated vasculitis: potential pitfalls and future prospects. Kidney360. 2021;2(4):586–597.
Scurt FG, Micheroli R, Bünzli S, et al. Old known and possible new biomarkers of ANCA-associated vasculitis. Rheumatol Int. 2022;42:1017–1030.
Shumnalieva R, Kolarov Z, Stoilov R, et al. New biomarkers for systemic necrotizing vasculitides. J Clin Med.
;13(8):2264.
Marvisi C, Arioli D, Gallelli L, et al. Biomarkers in ANCAassociated vasculitis: clinical utility, pitfalls and their
role in the outcomes assessment. Front Immunol. 2025;16:1616837.
Lee LE, Yoon T, Chung J, Ha JW, Park Y B, Lee S W. Serum glial # brillary acidic protein can predict cross-sectional vasculitis activity by re$ ecting renal involvement in patients with ANCA-associated vasculitis. Medicina. 2024;60(10):1639.
Yoon T, Ha JW, Park Y B, Lee S W. Serum Wnt3A in antibodyassociated vasculitis: associations with disease activity and renal outcomes. Clin Exp Rheumatol. 2025;43.
